Helen Goergen

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 386 citations

Medicine, Oncology, Radiation Oncology +12

Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

Karolin Behringer, Horst Mueller, Helen Goergen et al. · Journal of Clinical Oncology · 2012 · 261 citations · Full text

Medicine, Endocrinology, Oncology +14

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe et al. · Journal of Clinical Oncology · 2019 · 229 citations

Medicine, Nuclear Medicine, Oncology +14

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Karolin Behringer, Helen Goergen, Felicitas Hitz et al. · The Lancet · 2014 · 181 citations

Medicine, Oncology, Pharmacology +14

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Paul J. Bröckelmann, Helen Goergen, Ulrich Keller et al. · JAMA Oncology · 2020 · 169 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16